Deadline for hypoxic tumors
Moving personalized medicine from promise to practice. Siemens Healthcare announces the early study findings of a new imaging biomarker for hypoxic tumors. This clinically problematic cells tend to be less responsive to standard treatment regimens. A probe that measures hypoxia could prove quite a useful tool for oncologists.
Hypoxic cells are clinically problematic and tend to be less responsive to standard treatment regimens. A probe that measures hypoxia could prove quite a useful tool for oncologists. The development of an imaging biomarker that selectively identifies hypoxic tumor cells could help radiation oncologists tailor specific treatment options to most efficiently manage disease.
“Being able to image hypoxic tumors may significantly change the management of disease in cancer patients. The prognostic value of this level of information can effectively improve quality of life for oncology patients, offering them potential for personalized and possibly more effective treatment,” said Hartmuth Kolb, vice president, Siemens Molecular Imaging Biomarker Research.
The results of the safety study indicated that HX4, a new imaging biomarker developed at Siemens Molecular Imaging Biomarker Research, is safe for use in human positron emission tomography (PET) imaging studies. The study included initial human data regarding bio-distribution of the new agent, radiation dosimetry levels in normal volunteers and optimal patient imaging parameters with PET. Results of the study indicated that the compound was found to be stable for imaging at 145 minutes post injection, that it would safely clear the body through urinary elimination and that there were very low dose accumulations in major organs.
PETNET Solutions operates the largest PET radiopharmacy network with more than 50 radiopharmacies and distribution centers worldwide to produce and distribute PET radiopharmaceuticals to hospitals, clinics, and research facilities for PET imaging. PETNET Solutions is currently growing its network of radiopharmacies to promote global PET utilization. As molecular imaging evolves, PETNET Solutions delivers products and services that expand the value of PET to providers, referring physicians and patients. PETNET Solutions is delivering, expanding, and advancing the science of PET through high quality PET tracers. Further information can be found by visiting
.
19.09.2008
